Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Use of Multiple Myeloma 70-Gene Prognostic Risk Score As a Continuous Predicitor of Patient Outcome

Ryan van Laar, PhD, Richard A Bender, MD, Aga Zielinski, PhD, Kenton Leigh, BS, Bart Barlogie, MD PhD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 5614.

https://doi.org/10.1182/blood.V128.22.5614.5614

Published: 2016

Journal Articles

MyPRS R Molecular Subtypes of Multiple Myeloma Represent All High-Risk FISH Translocations Included in the mSMART 2.0 and R-ISS Guidelines

Ryan K Van Laar, PhD, Ivan Borrelo, MD, David Jabalayan, MSc, Ruben Niesvizky, MD, Aga Zielinski, PhD, Kenton Leigh, BS, Nathan Brown, PhD, Richard A Bender, MD

Blood (2016) 128 (22): 3264.

https://doi.org/10.1182/blood.V128.22.3264.3264

Published: 2016

Journal Articles

The 70-Gene MyPRS R prognostic Risk Score Signature Predicts Increased Risk of Progression from MGUS to Multiple Myeloma Requring Treatment

Ryan van Laar, PhD, Phillip Farmer, BS, Richard A Bender, MD, Aga Zielinski, PhD, Kenton Leigh, BS, Nathan Brown, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 3275.

https://doi.org/10.1182/blood.V128.22.3275.3275

Published: 2016

Journal Articles

Small RNA Next Generation Sequencing (NGS) of CD138+ Plasma Cells from Multiple Myeloma Patients and Comparison to the 70-Gene mRNA-Based Prognostic Risk Score

Ryan van Laar, PhD, Kenton Leigh, BS, Aga Zielinski, PhD, Nathan Brown, PhD, Richard A Bender, MD

Blood (2016) 128 (22): 2089.

https://doi.org/10.1182/blood.V128.22.2089.2089

Published: 2016

Journal Articles

Validation of the Nextseq 500 and Development of a High-Throughput NGS Pipeline for Identifying Clinically-Relevant Gene Variants in Multiple Myeloma Specimens

Agnieszka K. Zielinska, PhD, Kenton Leigh, BS, Horacio Gomez, PhD, Ryan K Van Laar, PhD

Blood (2015) 126 (23): 5346.

https://doi.org/10.1182/blood.V126.23.5346.5346

Published: 2015

NARROW

Use of Multiple Myeloma 70-Gene Prognostic Risk Score As a Continuous Predicitor of Patient Outcome

MyPRS R Molecular Subtypes of Multiple Myeloma Represent All High-Risk FISH Translocations Included in the mSMART 2.0 and R-ISS Guidelines

The 70-Gene MyPRS R prognostic Risk Score Signature Predicts Increased Risk of Progression from MGUS to Multiple Myeloma Requring Treatment

Small RNA Next Generation Sequencing (NGS) of CD138+ Plasma Cells from Multiple Myeloma Patients and Comparison to the 70-Gene mRNA-Based Prognostic Risk Score

Validation of the Nextseq 500 and Development of a High-Throughput NGS Pipeline for Identifying Clinically-Relevant Gene Variants in Multiple Myeloma Specimens

Email alerts

ASH Publications

American Society of Hematology

Use of Multiple Myeloma 70-Gene Prognostic Risk Score As a Continuous Predicitor of Patient Outcome

MyPRS R Molecular Subtypes of Multiple Myeloma Represent All High-Risk FISH Translocations Included in the mSMART 2.0 and R-ISS Guidelines

The 70-Gene MyPRS R prognostic Risk Score Signature Predicts Increased Risk of Progression from MGUS to Multiple Myeloma Requring Treatment

Small RNA Next Generation Sequencing (NGS) of CD138+ Plasma Cells from Multiple Myeloma Patients and Comparison to the 70-Gene mRNA-Based Prognostic Risk Score

Validation of the Nextseq 500 and Development of a High-Throughput NGS Pipeline for Identifying Clinically-Relevant Gene Variants in Multiple Myeloma Specimens

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only